Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329698 | 0.86 | CFD (0.40) | CFDCHRM1CHRM2CHRM3MEN1 | |
| SCHEMBL22355134 | 0.86 | CFD (0.40) | CFDCHRM1CHRM2CHRM3MEN1 | |
| SCHEMBL23308856 | 0.84 | CFD (0.38) | CFDCHRM1CHRM2CHRM3MEN1 | |
| SCHEMBL20329519 | 0.84 | CFD (0.39) | CFDCHRM1CHRM2CHRM3MEN1 | |
| SCHEMBL18572757 | 0.84 | CHRM1 (0.42) | CFDCHRM1CHRM2CHRM3MEN1 | |
| SCHEMBL22355131 | 0.84 | CHRM1 (0.42) | CFDCHRM1CHRM2CHRM3MEN1 | |
| SCHEMBL24093944 | 0.82 | CFD (0.35) | CFDCHRM1CHRM2CHRM3MEN1 | |
| SCHEMBL25097198 | 0.82 | CFD (0.35) | CFDCHRM1CHRM2CHRM3MEN1 | |
| SCHEMBL18590935 | 0.81 | ROCK2 (0.49) | CFDCHRM1CHRM2CHRM3CYP2C19 | |
| SCHEMBL18572835 | 0.81 | ROCK2 (0.49) | CFDCHRM1CHRM2CHRM3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CFD 1/4885CHRM1 4424/4885CHRM2 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.